Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions

Inclusion Criteria: * Age 8 years or older, including adults. * Sore throat or minor mouth lesion, including minor aphthous ulcer or histologically confirmed oral lichen planus, evolving for less than 15 days. * Global pain intensity over the previous 24 hours, spontaneous and/or during chewing or swallowing, \>40 mm on a 0-100 mm visual analog scale. * OROSEDAL prescription decided by the investigator before inclusion. * Written informed consent from the patient or from one parent for minors. Exclusion Criteria: * More than 3 visible oral mucosal lesions. * Post-intubation sore throat. * Corticosteroid use ongoing or within 3 days before inclusion. * NSAID use ongoing or within 3 days before inclusion. * Local treatment on the lesion ongoing or within 3 days before inclusion. * Non-opioid analgesics, including paracetamol, ongoing or within 3 days before inclusion, unless continued for at least 24 hours at the same daily dose as during the 24 hours before inclusion. * Weak or strong opioid analgesics ongoing or within 3 days before inclusion. * Signs suggesting a condition requiring additional investigations according to the investigator, except rapid streptococcal throat testing. * Signs suggesting a condition requiring corticosteroid prescription according to the investigator. * Systemic disease, such as rheumatoid arthritis, lupus, or Behçet disease. * Any contraindication listed in OROSEDAL instructions for use. * Known allergy to any OROSEDAL component, including glycerol, tamarind extract, mallow extract, benzyl alcohol, orange blossom flavoring, or xylitol. * Non-compliance with precautions for use listed in the instructions for use.